Skip to content

The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study

The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03491098
Acronym
Efficacy
Enrollment
60
Registered
2018-04-09
Start date
2018-05-15
Completion date
2020-03-01
Last updated
2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otitis Media With Effusion

Keywords

Otitis Media with Effusion

Brief summary

Otitis media with effusion (OME) is defined as effusion in the middle ear without signs and symptoms of an acute infection. It is a leading cause of hearing impairment in children, and its early and proper management can avoid hearing and speech impairment, which can cause developmental delay in children.Although many conditions such as enlarged adenoids, cleft palate, Down syndrome, Kartagener syndrome, and nasopharyngeal neoplasm are related to the role of eustachian tube (ET) dysfunction in the pathogenesis of OME, allergic, immunologic, and infectious factors have also been claimed. Treatment of OME is still a controversial issue, as conventional treatment approaches fail to provide satisfactory and permanent relief of otologic symptoms.There is lack of proven effectiveness of the commonly given treatments, such as antibiotics, decongestants, and antihistamines, which are potentially harmful and have disadvantages. Few in those studies,investigated topical intranasal steroid for OME treatment,and in those studies, the duration of intranasal steroid application was short and there was no hearing evaluation.

Detailed description

The aim of this study is to assess the efficacy of nasal steroids in management of OME by comparing its results with that of oral steroids and that of nasal saline spray. Sixty patients (4-12) years aged children with OME over a period for two months will be included in this study. Informed written consent will obtained from the parents of patient studied after explanation of the research purpose. Patient diagnosed clinically to have OME with type B tympanogram and conductive hearing loss will be enrolled in our study. Exclusion criteria: 1. Patients previously managed by ventilation tube. 2. Those who had cleft palate. The patients were divided into three equal groups. In group 1, 20 patients will be received steroids spray, for. 2 months In group 2, 20 patients will be received steroids for 1 month In group 3, 20 patients will be receive hypertonic sea water solution Otoscopic examination, basic audiological evaluation including pure tone audiometry, and immittancemetry will be performed before treatment and repeated at 3 and 6 months after treatment. The evaluation was performed using ORBITR 922 VERSION2 . Examiners will be blinded to the type of treatment. Tympanometry results were distinguished into four grades as classified by El-Anwar et al12: type A, normal curve (pressure 50/\_99 H2O); type C1 (negative pressure \_100/\_199 mm H2O); type C2 (negative pressure \_200/\_394 mm H2O); type B (flat curve).2,3,11 The average hearing thresholds at 500 Hz and 1, 2, and 4 kHz were used in the statistical comparison. Follow-up clinical examinations were done once per week for 3 weeks, at the end of treatment. The efficacy of nasal steroid for management of OME was compared with that of oral steroid and that of nasal sinomarin spray as placebo.

Interventions

DRUGMometasone Furoate spray

Mometasone Furoate spray one puff in each nostril daily for 8 weeks hypertonic sea water solution spray one puff in each nostril daily for (8) weeks.

DRUGprednisolone sodium phosphate 15mg

three times per day for 1 week then gradual withdrawal over 2 weeks

DRUGhypertonic sea water solution spray

one puff in each nostril daily for 8 weeks

Sponsors

Muteea Mubark Salmen Bakuwiri
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Sixty patients (4-12) years aged children with OME over a period for two months.

Exclusion criteria

* Patients previously managed by ventilation tube. * Those who had cleft palate.

Design outcomes

Primary

MeasureTime frameDescription
Clinical examination:Hearing loss2 weeks evaluation for 2 monthsHearing loss,0=no symptoms,1= present 2 weeks ,3=present daily,4=always present,
Clinical examination:Nasal obstruction2 weeks evaluation for 2 monthsNasal obstruction,0=no symptoms,1= present 2 weeks ,3=present daily,4=always present,
Full E.N.T history2 weeks evaluation for 2 monthsSnoring ,sleep apnea ,difficult suckling in infants,anterior nasal discharge and conductive hearing loss.

Contacts

Primary ContactMuteea M Bakuwairi, master
bakuwairi2017@gmail.com01148883026

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026